Apple Inc. AAPL business primarily runs around its flagship iPhone.However, the Services portfolio that includes revenues from cloud services, App store, Apple Music, AppleCare, Apple Pay, and licensing and other services now became the cash cow. Apple’s second-quarter fiscal 2021 results reflected continued momentum in the Services segment, driven by a robust performance of App Store, Cloud Services, Music, advertising and AppleCare. Moreover, iPad, Mac and Wearables contributed strongly to the quarterly results. Further, iPhone sales increased due to strong demand for iPhone 12 devices. China and Japan iPhone sales increased significantly. Apple currently has more than 620 million paid subscribers across its Services portfolio. Apple’s focus on autonomous vehicles and augmented reality/virtual reality (AR/VR) technologies presents growth opportunity in the long haul. Apple has a strong balance sheet and generates significant cash flow.Chewy Inc. CHWY operates as an online pet retailer.Prudent saving measures, rising online sales and focus on portfolio enhancement and innovation have been working in favor of this company. The provider of pet food and treats, pet supplies and medications, and other pet-health products has been benefiting from the rising pet adoption rates amid the pandemic as people seek comfort and companionship. Apart from this, consumers’ increased preference for e-commerce mode of shopping, especially amid the pandemic, has been working well for this company. Markedly, Chewy has been focused on strengthening its customer base as well as curtailing expenses. The company has an expected long-term earnings growth rate of 20%. It is also important to note the recent changes to analyst estimates for CHWY. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. CHWY is holding a Zacks Rank of #2 (Buy) right now and currently has a Growth Score of ‘A’.Breakout Biotech Stocks with Triple-Digit Profit PotentialThe biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Apple Inc. (AAPL): Free Stock Analysis Report Chewy Inc. (CHWY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research